论文部分内容阅读
BACKGROUND:?Lamivudine?and?hepatitis?B?immunoglobulin?(HBIG)? are? widely? used? to? treat? patients? with? hepatitis? B?recurrence?after?liver?transplantation.?However,?the?outcomes?are?inconclusive.?The?present?study?was?undertaken?to?evaluate?the? effect? of? combined? therapy? on? patients? with? hepatitis? B?recurrence?after?liver?transplantation. METHODS:?Twenty-two? patients? with? hepatitis? B? recurrence?after?liver?transplantation?from?August?2000?to?October?2011?were? enrolled? in? this? study.? Of? these? patients,? 16? received?lamivudine?plus?HBIG?(combination?therapy?group)?and?6?were?treated? with? lamivudine? alone? (lamivudine-treated? group).?The? clinical? features? were? matched? in? the? two? groups.? HBV?recurrence?parameters,?HBsAg?clearance?rate,?patient?survival?rate,?and?survival?time?were?compared. RESULTS:?The? average? time? of? follow-up? was? 47.2? months?(range?13-99).?Significant?difference?was?noted?in?the?HBsAg?clearance? rate? in? the? lamivudine-treated? and? combination?therapy?groups?(50%?vs?93.8%,?P0.05). CONCLUSION:?Compared? with? lamivudine? monotherapy,?combination?therapy?significantly?increased?the?HBsAg?clearance?rate?in?patients?with?HBV?recurrence?after?liver?transplantation.